Costs and benefits of direct-to-consumer advertising: The case of depression

PharmacoEconomics

Volumn 25, Issue 6, 2007, Pages 511-521

  Block, Adam E ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATORVASTATIN; ESOMEPRAZOLE; FLUOXETINE; MONTELUKAST; PAROXETINE; SERTRALINE;

ADVERTIZING; ARTICLE; CONSUMER HEALTH INFORMATION; COST BENEFIT ANALYSIS; DEPRESSION; EPIDEMIOLOGICAL DATA; EXPERIMENTAL STUDY; HEALTH CARE; HEALTH SURVEY; MATHEMATICAL MODEL; PRESCRIPTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOCIAL WELFARE;

ADVERTISING; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; HUMANS; MODELS, ECONOMIC; UNITED STATES;

EID: 34249802937     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725060-00006     Document Type: Article

References (27)

1. Harder B. Pushing drugs. Science News July 30 2005; 168 (5): 75 [online]. Available from URL: http://www.sciencenews. org/articles/20050730/bob10.asp [Accessed 2007 May 2]
2. Rosenthal M, Berndt E, Donahue J, et al. Promotion of prescrip tion drugs to consumers. N Engl J Med 2002; 346 (7): 498-505
3. Spence MM, Teleki SS, Cheetham TC, et al. Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005 Oct; 62 (5): 544-59
4. Galbraith JK. The affluent society. Boston (MA): Houghton-Mifflin Company, 1958: 155-6
5. Becker G, Murphy K. A simple theory of advertising as a good or bad. Q J Econ 1993; 108 (4): 941-64
6. Iizuka T, Jin GZ. The effect of prescription drug advertising on doctors visits. J Econ Manag Strategy Sept 2005; 14 (3): 701-27
7. Donahue J, Berndt E. Effects of direct-to-consumer advertising on medication choice: the case of antidepressants. J Public Policy Marketing 2004; 23 (2): 115-27
8. Widespread belief that antidepressants are prescribed too often, particularly for teens and children. WSJOnline June 2004; 3 (12) [online]. Available from URL: http://www.harrisinteractive.com/news/newsletters/ wsjhealthnews/WSJOnline_HI_Health-CarePoll2004vol3_iss12.pdf [Accessed 2006 Nov 14]
9. Rosenthal MB, Berndt ER, Donohue JM, et al. Demand effects of recent changes in prescription drug promotion. In: Cutler DM, Garber AM, editors. Frontiers in health policy research. Vol. 6. Cambridge (MA): MIT Press, 2003
10. Weissman JS, Blumenthal D, Silk AJ, et al. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff (Millwood 2003; web suppl: W3-82-95
11. Kessler R, Berglund P, Demler O, et al. The epidemiology of major depressive disorder. JAMA 2003; 289: 3095-105
12. Kravitz R, Epstein R, Feldman M, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants. JAMA 2005; 293: 1995-2002
13. Slaughter E. Consumer reaction to DTC advertising of prescription medicines 1997 to 2002. FDA presentation, 2003 Sep 25 [online]. Available from URL: http://www.fda.gov/cder/ddmac/P1Slaughter/index.htm [Accessed 2006 Mar 23]
14. National Ambulatory Medical Care Survey: 2000 Summary Number 328. Washington, DC: National Center for Health Statistics, 2002 Jun 5
15. About.com. US Gov Info/Resources [online]. Available from URL: http://usgovinfo.about.com/cs/censusstatistic/a/latestpo pcounts.htm [Accessed 2007 May 3]
16. The Henry J. Kaiser Family Foundation. Understanding the effects of direct-to-consumer prescription drug advertising. Menlo Park (CA): The Henry J. Kaiser Family Foundation, November 2001 [online]. Available from URL: http://www.kff.org/rxdrugs/upload/Understanding-the-Effects-of-Direct-to- Consumer-Prescription-Drug-Advertising-Report.pdf [Accessed 2007 May 14]
17. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286 (23): 2947-55
18. Young AS, Klap R, Sherbourne CD, et al. The quality of care of depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001; 58 (1): 55-61
19. Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs 2006; 20 (8): 623-32
20. US Food and Drug Administration, Center for Drug Evaluation and Research. Aiken KJ. Direct-to-consumer advertising of prescription drugs: physician survey preliminary results [on line]. Available from URL: http://www.fda.gov/ cder/ddmac/globalsummit2003 [Accessed 2006 May 1]
21. Nurnberg HG, Hensley PL, Thompson PM, et al. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors. Psychiatr Serv 1999; 50 (10): 1351-3
22. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163 (1): 28-40
23. Frank RG, McGuire TG, Normand SL, et al. The value of mental health care at the system level: the case of treating depression. Health Aff (Millwood) 1999; 18 (5): 71-88
24. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132 (9): 743-56
25. Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care: rate and clinical predictors. Arch Fam Med 1998; 7 (5): 443-9
26. Cutler, DM. Your money or your life. New York (NY): Oxford University Press, 2004
27. Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Medical Care 2004; 42 (12): 1176-85